In vitro sensitivity to 5-FU and gemcitabine in pancreatic cancer

被引：0
|
作者：
Franko, J.
Bilimoria, M. M.
Chalikonda, S.
Iannitti, D. A.
机构：
[1] Mercy Med Ctr, Des Moines, IA USA
[2] Adv Surg Associates, Arlington Hts, IL USA
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Carolinas HealthCare Syst, Charlotte, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
312
引用
收藏
页数：1
相关论文
共 50 条
  • [21] nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
    Ueno, Makoto
    Nakamori, Shoji
    Sugimori, Kazuya
    Kanai, Masashi
    Ikeda, Masafumi
    Ozaka, Masato
    Furukawa, Masayuki
    Okusaka, Takuji
    Kawabe, Ken
    Furuse, Junji
    Komatsu, Yoshito
    Ishii, Hiroshi
    Sato, Atsushi
    Shimizu, Satoshi
    Chugh, Priti
    Tang, Rui
    Ioka, Tatsuya
    CANCER MEDICINE, 2020, 9 (24): : 9396 - 9408
  • [22] A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer
    Riess, H
    Helm, A
    Niedergethmann, M
    Schmitt-Wolf, I
    Moik, M
    Hammer, C
    Zippel, K
    Weigang-Köhler, K
    Stauch, M
    Oettle, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 310S - 310S
  • [23] Synthesis and biological evaluation of novel 5-FU analogs against pancreatic cancer
    Frimpong, Esther
    Bulusu, Raviteja
    Okoro, Joy
    Inkoom, Andriana
    Ndemazie, Nkafu
    Rogers, Sherise
    Zhu, Xue
    Han, Bo
    Agyare, Edward
    CANCER RESEARCH, 2024, 84 (06)
  • [24] A CONTROLLED TRIAL OF COMBINATION CHEMOTHERAPY WITH 5-FU AND BCNU IN PANCREATIC-CANCER
    ANDERSEN, JR
    FRIISMOLLER, A
    HANCKE, S
    RODER, O
    STEEN, J
    BADEN, H
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1981, 16 (08) : 973 - 975
  • [25] Synergistic effect of TTF and 5-FU combination treatment on pancreatic cancer cells
    Jo, Yunhui
    Lee, Eunjun
    Oh, Geon
    Gi, Yongha
    Yoon, Myonggeun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (10): : 4734 - 4741
  • [26] Establishment and molecular profiling of a novel human pancreatic cancer panel for 5-FU
    Yanagihara, Kazuyoshi
    Takigahira, Misato
    Tanaka, Hiromi
    Arao, Tokuzo
    Aoyagi, Yasuyuki
    Oda, Tatsuya
    Ochiai, Atsushi
    Nishio, Kazuto
    CANCER SCIENCE, 2008, 99 (09) : 1859 - 1864
  • [27] Colorectal cancer - Is there an alternative to 5-FU?
    Bleiberg, H
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (04) : 536 - 541
  • [28] LncRNA TUG1 is a potent therapeutic target via enhancing 5-FU sensitivity in pancreatic cancer.
    Tasaki, Yoshihiko
    Katsushima, Keisuke
    Shinjo, Keiko
    Suzuki, Miho
    Iijima, Kenta
    Miyata, Kanjiro
    Kataoka, Kazunori
    Kimura, Kazunori
    Kondo, Yutaka
    CANCER SCIENCE, 2021, 112 : 440 - 440
  • [29] Schizandrin A enhances the sensitivity of gastric cancer cells to 5-FU by promoting ferroptosis
    Hu, Liye
    Zhang, Zhongyuan
    Zhu, Feng
    Li, Xin
    Zou, Min
    Yang, Rui
    CYTOTECHNOLOGY, 2024, 76 (03) : 329 - 340
  • [30] Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the formation of pancreatic cancer stem like cells
    Cho, Jae Hee
    Kim, Sun A.
    Park, Soo Been
    Kim, Hee Man
    Song, Si Young
    ONCOTARGET, 2017, 8 (44) : 76398 - 76407
12345